NEXUS BIOPHARMA INC
NEXUS BIOPHARMA INC (NEXS): 49 pipeline candidates · ~0 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
0.3 months
0% dilution
Lead: Approved
49 candidates
N/A
N/A
A transparent, data-derived signal for NEXUS BIOPHARMA INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$8K
Quarterly Burn
$92K
Runway
0.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (49 candidates)
| Drug | Phase |
|---|---|
| arsenic tri | Approved |
| arsenic tri | Approved |
| busulfan | Approved |
| busulfan | Approved |
| cyclophosphamide | Approved |
| cyclophosphamide | Approved |
| dicyclomine | Approved |
| dicyclomine | Approved |
| emerphed | Approved |
| emerphed | Approved |
Showing 10 of 49 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in NEXUS BIOPHARMA INC's pipeline?
NEXUS BIOPHARMA INC (NEXS) has 49 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NEXUS BIOPHARMA INC's lead drug candidate?
NEXUS BIOPHARMA INC's most advanced tracked candidate is arsenic tri (Approved) for 1 INDICATIONS AND USAGE Arsenic Trioxide Injection is an arsenical indicated: For induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. ( 1.2 ) 1.2 Relapsed or Refractory APL Arsenic Trioxide Injection is indicated for induction of remission and consolidation in patients with APL who are refra.
What is NEXUS BIOPHARMA INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NEXUS BIOPHARMA INC has approximately 0.3 months of cash runway.
Who is the CEO of NEXUS BIOPHARMA INC?
Warren Lau Warren is the chief executive officer of NEXUS BIOPHARMA INC (NEXS).
Get the full picture on NEXUS BIOPHARMA INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.